Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025
CORAL GABLES, Fla., March 26, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, or “the Company”),…
0,543€
6,37%
Echtzeit-Aktienkurs Relmada Therapeutics
Bid:
Ask:
Nachrichten zur Relmada Therapeutics Aktie
Relmada Therapeutics faces potential Nasdaq delisting By Investing.com
Relmada Therapeutics faces potential Nasdaq delisting…
Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017
Relmada Therapeutics has Commenced a Process to Explore Strategic Alternatives to Maximize Shareholder Value Relmada Therapeutics has Commenced a Process…
Relmada Therapeutics, Inc. (RLMD) Q3 2024 Earnings Call Transcript
…
Relmada Therapeutics, Inc. (RLMD) Q2 2024 Earnings Call Transcript
…
Relmada Therapeutics to Report Second Quarter 2024 Financial Results on August 7, 2024
CORAL GABLES, Fla., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”), a late-stage biotechnology…
Relmada Therapeutics, Inc. (RLMD) Q1 2024 Earnings Call Transcript
…
Earnings call: Relmada Therapeutics reports progress in Phase 3 trials By Investing.com
Earnings call: Relmada Therapeutics reports progress in Phase 3 trials…
Relmada Therapeutics, Inc. (RLMD) Q4 2023 Earnings Call Transcript
…
Relmada Therapeutics FY 2023 Earnings Preview
…